Objective To compare the efficacy of S-adenosyl-L-methionine and ursodeoxycholic acid in improving serum biochemical abnormalities in gestational cholestasis. Design Randomised clinical trial.
INTRODUCTION
Gestational cholestasis, an intrahepatic form of cholestasis that occurs during the second half of pregnancy, is characterised by intense pruritus and abnormalities of liver function tests and bile acids. In most cases, the onset is in the last weeks of pregnancy and the women do not require treatment, either because the symptoms are mild or because the pregnancy is terminated. Onset of cholestasis early in pregnancy gestation with severe symptoms and serum biochemical abnormalities is often considered an indication for treatment. Of the several therapies proposed for this condition, ursodeoxycholic acid and S-adenosyl-Lmethionine have been shown in several studies to have a beneficial effect on serum biochemical abnormalities. Their mechanism of action is thought to be enhancement of excretory hepatocyte function and choleretic activity, stabilisation of hepatocyte cell membrane and dilution of the more toxic bile acids in the enterohepatic circulation. 1 Ursodeoxycholic acid normalises the ratio of 3a to 3h hydroxysteroid in women with obstetric cholestasis and decreases the accumulation of bile acids in the fetus. 2, 3 S-Adenosyl-L-methionine is implicated in methylation reactions, and in animal experiments, it protects against hormone-induced cholestasis by facilitating the transsulphuration of bile salts into excretory forms. 4 Anecdotal evidence suggests that improvement in serum biochemical abnormalities may also result in improved pruritus and perinatal outcome. A recent meta-analysis of the efficacy of the two treatments concluded that the evidence currently available does not allow firm conclusions as to the more effective therapy. 5 We conducted a randomised clinical trial to compare the efficacy of S-adenosyl-L-methionine and ursodeoxycholic acid in lowering serum bile acids in women with gestational cholestasis.
METHODS
During June 1996 to December 2001, all women with gestational cholestasis at a gestational age of less than 36 weeks at the Department of Obstetrics and Gynecology of the University of Milano-Bicocca were invited to participate in our randomised clinical trial. Gestational cholestasis was diagnosed by generalised pruritus starting in the second or third trimester of pregnancy, persisting to delivery and disappearing after delivery, in the absence of other medical conditions known to be associated with pruritus. 6 The diagnosis had to be supported by elevation of the concentration of the concentration of bile acids above the reference range for the laboratory ( >6 Amol/L), or elevation in the concentrations of serum transaminases (>41 mg/dL). Pruritus was scored by a semiquantitative scale of 1 -4, with grade 1 ¼ occasional pruritus, grade 2 ¼ daily intermittent pruritus with preponderance of asymptomatic periods, grade 3 ¼ daily intermittent pruritus with preponderance of symptomatic periods and grade 4 ¼ persistent pruritus, day and night. Such a score has already been validated by independent investigators. 3, 4 The women gave their consent to the trial, which was approved by the Institutional Review Board of the hospital. The women were assigned by computer-generated random number tables to receive either oral S-adenosyl-L-methionine 500 mg twice daily or oral ursodeoxycholic acid 300 mg twice daily until delivery. There was no concealment of the treatment allocation. Cross over was not contemplated even in presence of persistent symptoms and no other medications were used to improve pruritus and liver function tests. The primary goal of the study was reduction of the concentration of serum bile acids (normal level: 2.23 [standard deviation, SD, 1.95] Amol/L). Under the assumption that a difference of 1 SD in the reduction of the concentration of serum bile acids between the two treatments was clinically significant, at least 16 women would be required in each group to achieve statistical significance (alpha ¼ 0.05, beta ¼ 0.80).
All women enrolled in the study underwent serial evaluations of liver function tests (aspartate aminotransferases, alanine aminotransferases, bile acids and bilirubin) every 7-10 days and monitoring of fetal wellbeing with twice weekly non-stress tests and amniotic fluid volume determination, starting at the time of fetal viability. A biophysical profile was performed if the non-stress test was non-reactive. Given the prognostic significance of the presence of meconium-tinged amniotic fluid in obstetric cholestasis, 7 amniotic fluid colour was assessed weekly, beginning at 36 weeks, using transcervical amnioscopy if the cervix was patent to the amnioscope, or amniocentesis. The presence of meconium was considered by itself to be an indication for delivery. Labour was induced at 37 weeks of gestation or earlier in the presence of abnormal tests of fetal wellbeing, obstetric complications or severe maternal symptoms unresponsive to therapy, where the fetal lungs were mature. Fetal growth restriction was defined as an abdominal circumference below the 10th centile according to our national standards. Fetal lung maturity was assessed at 37 weeks of gestations only in the presence of diabetes mellitus or uncertain gestational age. If the results indicated immature fetal lungs, amniocentesis was repeated at weekly intervals until maturity or meconium was seen. Follow up assessment of serum liver function tests was performed one and three months after delivery. Statistical analysis was performed with Student's t test for continuous variables that were normally distributed, the Wilcoxon's signed rank sum test for ordinal variables, the Mann -Whitney U test for continuous variables that were not normally distributed, Fisher's exact test and the m 2 for dichotomous variables and Spearman's rank correlation test. A two-tailed P < 0.05 or a relative risk (RR) with 95% confidence interval (CI) not inclusive of unity were considered significant.
RESULTS
During the study, 158 cases of intrahepatic cholestasis of pregnancy were identified of 16,255 women (incidence 1%). All of the 46 women (29%) with gestational cholestasis diagnosed before 36 weeks of gestation agreed to participate in the study: 22 women were randomised to S-adenosyl-L-methionine and 24 to ursodeoxycholic acid. Table 1 displays the characteristics of the women at enrolment. There were no significant clinical differences between the two groups in any of the variables considered. There were three twin gestations, one in the ursodeoxycholic acid group and two in the S-adenosyl-L-methionine group. For the purpose of statistical analysis of neonatal outcome, we included only one twin chosen at random. Mean [SD] duration of therapy was 27.1 [14.8] days (range 3 -63 days) in the group of women treated with ursodeoxycholic acid and 18.2 [13.5] days (range 4 -54 days) among those treated with S-adenosyl-L-methionine ( P ¼ 0.04). We calculated the effects of the treatments on the laboratory variables by subtracting the last values before delivery from those at enrolment (Table 2) . Negative values reflect reduction in the value from enrolment until delivery. Women receiving ursodeoxycholic acid had an improvement in all of the laboratory variables considered, whereas those randomised to S-adenosyl-L-methionine did not. No correlation was observed between the duration of therapy and the difference in serum bile acids between enrolment and delivery (ursodeoxycholic acid: r ¼ 0.18, P ¼ 0.49; S-adenosyl-L-methionine: r ¼ 0.18, P ¼ 0.54). Both treatments similarly improved pruritus score (Table 3) , with 14/24 (58%) women showing a reduction in score at the last visit before delivery in the ursodeoxycholic acid group and 13/22 (59%) in the S-adenosyl-L-methionine group.
Gestational age at delivery and rate of preterm delivery were similar in the two groups ( Table 4 ). The leading cause of preterm delivery was spontaneous prematurity, with 3/3 cases in the ursodeoxycholic acid group and 5/10 in the S-adenosyl-L-methionine group. Labour was induced before 37 weeks of gestation for worsening maternal symptoms in three women in the S-adenosyl-L-methionine group and none in the ursodeoxycholic acid group. Despite the low average gestational age at delivery in the whale study, 15% (7/46) of pregnancies had meconium passage, either before (three) or during labour (four). There was a tendency towards a reduction in the rate of passage of meconium in the ursodeoxycholic acid group. The rates of admission to the neonatal intensive care unit were not significantly different. Indications for admission to the neonatal intensive care unit were neonatal sepsis in one case, cardiac defect in one, twin-to-twin transfusion syndrome in two twins, low birthweight in two cases, hypoglycaemia or hyperbilirubinaemia in four and mild respiratory distress in two cases. No adverse effects were noted on the fetuses or neonates with either therapy. 
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DISCUSSION
We have completed the largest randomised clinical trial to date comparing the efficacy of S-adenosyl-L-methionine and ursodeoxycholic acid in the treatment of gestational cholestasis. We have found that ursodeoxycholic acid is more effective than S-adenosyl-L-methionine at improving the maternal laboratory findings associated with cholestasis. Results similar to ours have been reported by the two other randomised trials comparing ursodeoxycholic acid and S-adenosyl-L-methionine. 8, 9 In addition, two small randomised trials comparing ursodeoxycholic acid and placebo also showed a significant improvement in laboratory measurements with ursodeoxycholic acid. 3, 10 Previous studies compared the effects of therapy only in women who completed at least 10 days of therapy; however, in our study duration of therapy did not seem to be related to the effect on the S-adenosyl-L-methionine concentrations of serum bile acid.
Although S-adenosyl-L-methionine appeared to be less effective than ursodeoxycholic acid at improving laboratory measurements, there is contrasting evidence in the literature regarding its efficacy in comparison with placebo. A clinical trial of 18 women randomised to receive either S-adenosyl-L-methionine or placebo did not find a significant difference between the two groups in any of the laboratory measurements considered, 4 whereas a similar randomised trial detected a significant reduction in serum bile acids and transaminase levels with S-adenosyl-L-methionine. 11 It is possible that these contrasting findings may reflect different dosages and routes of administration, as well as differences among populations in their response to the therapy. Synergism may be present between ursodeoxycholic acid and S-adenosyl-L-methionine, as a randomised clinical trial showed that the two treatments combined are more effective than either therapy alone at improving laboratory parameters. 9 In our study, both S-adenosyl-L-methionine and ursodeoxycholic acid were equally effective at alleviating pruritus. Similar findings have been reported in another small trial of ursodeoxycholic acid and S-adenosyl-Lmethionine. 9 Previous clinical trials in which S-adenosyl-L-methionine or ursodeoxycholic acid were compared with placebo demonstrated a significant reduction in pruritus score with either medication. 3, 10, 11 At variance with our findings, a small trial in which 20 women were randomised to ursodeoxycholic acid or S-adenosyl-L-methionine reported greater efficacy with ursodeoxycholic acid on pruritus. 8 It is possible that the variable results on the efficacy of the two therapies on maternal pruritus may reflect different dosages and routes of administration of S-adenosyl-L-methionine, as well as the difficulty in grading pruritus in a reproducible fashion.
Our study was not large enough to assess whether either therapy had an effect on the risk of fetal mortality associated with gestational cholestasis. However, several lines of indirect evidence suggest that lowering serum bile acids may reduce fetal mortality. First, the risk of fetal death has been related to the serum levels of biliary acids. 12 An in vitro study suggests that biliary acids may have a vasoconstrictive effect on the placental cotyledons. 13 Another in vitro study using cultured cardiomyocites has shown that the bile acid taurocholate impairs rat cardiomyocyte function via altered calcium dynamics and loss of synchronous beating.
14 This finding suggests that raised levels of this bile acid in the fetal serum may cause fetal dysrhythmia and sudden intrauterine death. Of interest, most fetal deaths occurring in the context of gestational cholestasis are associated with meconium passage, 7, 15 possibly reflecting a direct toxic effect of meconium on umbilical cord vessels. 16, 17 We observed a non-significantly lower rate of meconium passage at delivery in the ursodeoxycholic acid group (8% vs 23%) compared with S-adenosyl-L-methionine. Because the risk of fetal death associated with cholestasis has been significantly reduced with a policy of intensive monitoring of fetal wellbeing, including amnioscopy for the detection of meconium-stained amniotic fluid and elective delivery at 37 weeks of gestation, 18 it is unlikely that future studies employing such monitoring practices will be large enough to establish the effect of therapy on fetal mortality. 
